JP2009534358A5 - - Google Patents

Download PDF

Info

Publication number
JP2009534358A5
JP2009534358A5 JP2009505894A JP2009505894A JP2009534358A5 JP 2009534358 A5 JP2009534358 A5 JP 2009534358A5 JP 2009505894 A JP2009505894 A JP 2009505894A JP 2009505894 A JP2009505894 A JP 2009505894A JP 2009534358 A5 JP2009534358 A5 JP 2009534358A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally
group
substituted
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009505894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534358A (ja
Filing date
Publication date
Priority claimed from GBGB0607944.6A external-priority patent/GB0607944D0/en
Application filed filed Critical
Publication of JP2009534358A publication Critical patent/JP2009534358A/ja
Publication of JP2009534358A5 publication Critical patent/JP2009534358A5/ja
Pending legal-status Critical Current

Links

JP2009505894A 2006-04-21 2007-04-19 アデノシンａ３受容体アゴニスト Pending JP2009534358A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607944.6A GB0607944D0 (en) 2006-04-21 2006-04-21 Organic compounds
PCT/EP2007/053847 WO2007147659A1 (en) 2006-04-21 2007-04-19 Adenosine a3 receptor agonists

Publications (2)

Publication Number Publication Date
JP2009534358A JP2009534358A (ja) 2009-09-24
JP2009534358A5 true JP2009534358A5 (enExample) 2011-03-10

Family

ID=36581041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505894A Pending JP2009534358A (ja) 2006-04-21 2007-04-19 アデノシンａ３受容体アゴニスト

Country Status (12)

Country Link
US (1) US20090281126A1 (enExample)
EP (1) EP2013199A1 (enExample)
JP (1) JP2009534358A (enExample)
KR (1) KR20080110845A (enExample)
CN (1) CN101426785A (enExample)
AU (1) AU2007263237B2 (enExample)
BR (1) BRPI0710514A2 (enExample)
CA (1) CA2649648A1 (enExample)
GB (1) GB0607944D0 (enExample)
MX (1) MX2008013520A (enExample)
RU (1) RU2008145708A (enExample)
WO (1) WO2007147659A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
CN101827847A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 用作腺苷a1受体配体的嘌呤衍生物
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
CA2732320C (en) 2008-08-01 2017-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) * 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
CZ203998A3 (cs) * 1996-01-02 1999-11-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Způsob přípravy 2,4-dihydroxypyridinu a 2,4-dihydroxy-3-nitropyridinu
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
PT1140933E (pt) * 1998-12-31 2004-12-31 Aventis Pharma Inc Processo para preparar derivados n6-substituidos de desaza-adenosina
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
JP4012070B2 (ja) * 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1699459B1 (en) * 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
ES2432113T3 (es) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
EP1794162A1 (en) * 2004-09-09 2007-06-13 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Purine derivatives as a3 and a1 adenosine receptor agonists
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US7176172B2 (en) * 2004-10-25 2007-02-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Quaternary ammonium polyol salts as anti-aging actives in personal care compositions
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
JP5048520B2 (ja) * 2005-02-04 2012-10-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
EP1959939B1 (en) * 2005-11-30 2012-01-11 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
EP1983990B1 (en) * 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators
SG169369A1 (en) * 2006-02-02 2011-03-30 Millennium Pharm Inc Inhibitors of e1 activating enzymes
ATE549337T1 (de) * 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
CN101827847A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 用作腺苷a1受体配体的嘌呤衍生物

Similar Documents

Publication Publication Date Title
TWI805255B (zh) 拮抗藥與免疫核查點阻礙藥而成之組合的用途
TWI739666B (zh) 醫藥組成物
JP2014506599A5 (enExample)
AU2018221820A1 (en) Processes for the preparation of benzodiazepine derivatives
WO2001085730A1 (en) Pyrido' 1,2-alpha pyrazine and piperidine derivatives as ligands for the neuropeptide y y5 receptor
JP2005537255A5 (enExample)
JP2016506960A5 (enExample)
JP2016535732A5 (enExample)
WO2008005914A3 (en) Novel glucokinase activators and methods of using same
JP2017533968A5 (enExample)
JP2013508373A5 (enExample)
JP2011513410A5 (enExample)
JP2015504076A5 (enExample)
JP2006502119A5 (enExample)
JP2012522766A5 (enExample)
CA2654315A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
EP3209652A1 (en) Tricyclic atropisomer compounds
JP2005517008A5 (enExample)
RU2007143509A (ru) Производные ацетилена
WO2017197151A1 (en) Phosphotidylinositol 3-kinase inhibitors
TW200616634A (en) Crystalline forms and process for preparing spiro-hydantoin compounds
JP2012509262A5 (enExample)
JP2014508178A5 (enExample)
CA2534003A1 (en) 3-quinuclidinyl-n-biarylamides as nicotinic acetylcholine receptor agonists